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The polymorphisms in Toll-like receptor genes
and cancer risk
Abstract
Toll-like receptors (TLRs) are a family of pattern recognition receptors
and have important role in pathogen recognition including activation of
innate and acquired immune responses. They are mainly expressed in
epithelium but have also been found in cancer cells, where they can have
pro-tumorigenic and anti-tumorigenic effect. Single nucleotide polymor-
phisms (SNPs) may change protein structure and influence receptor func-
tion. Polymorphisms in TLR genes have been linked with various cancer
types and reports were often contradictory. The strongest association with
increased cancer risk was found for TLR2 polymorphism –196 to –174 del
(D22) (gastric, gallbladder and cervical cancer) and TLR4 polymorphisms
rs4986790 (gastrointestinal cancers and lymphoma) and rs4986791 (gastro-
intestinal cancers, nasopharyngeal and gallbladder cancer). Other polymor-
phisms associated with cancer risk include TLR10-TLR1-TLR6 gene cluster
polymorphisms rs10008492 (non-Hodgkin’s lymphoma) and rs7696175
(breast cancer), TLR6 rs5743815 (non-Hodgkin’s lymphoma), TLR10
rs11466657 (meningioma), TLR2 GT microsatellite repeat number poly-
morphism (colorectal cancer) and rs3804100 (MALT lymphoma), TLR3
829A>C (nasopharyngeal cancer), TLR4 11350G>C (nasopharyngeal
cancer), rs1927911 and rs10759931 (prostate cancer), TLR5 rs5744174
(gastric cancer) and TLR9 rs5743836 (Hodgkin’s lymphoma) and rs352140
(Hodgkin’s lymphoma and cervical cancer). Discrepancies in results of
different studies regarding TLR polymorphisms and cancer risk may have
arissen due to insufficient sample size, differences in ethnicity or age,
undetected infections or other environmental factors.
1. INTRODUCTION
Toll-like receptors (TLRs) are a family of innate immune receptorsknown as pattern recognition receptors (PRRs) and they recognize
molecular motifs related to pathogens or pathogen associated molecular
patterns (PAMPs) (1). TLRs have a crucial role in recognition of many
different pathogens, including viruses, bacteria, protozoa and fungi, and
due to their important function, they are evolutionary conserved (2).
They were first described in Drosophila in 1984, and were later discovered
in vertebrates, including humans (1, 3). To date, 13 TLRs were disco-
vered in mammals, and 10 are functional in humans (2). Human genes
encoding TLRs reside on chromosomes 1 (TLR5), 3 (TLR9), 4 (TLR1,
TLR2, TLR3, TLR6 and TLR10), 9 (TLR4) and X (TLR7 and TLR8)
(1, 4). TLR signaling begins with binding of specific ligand, continues
with dimerization and signal transduction into the cell followed by
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activation of three main transcription factors: interferon-
-regulatory factor (IRF3, IRF5 and IRF7), NF-kB and
AP1. They then promote the transcription of inflamma-
tion mediators: cytokines, chemokines and interferons
(2, 5). TLRs are also important in activation of adaptive
immunity: downstream signaling and expression of cyto-
kines leads to maturation of dendritic cells and activation
of B and T cells (5).
2. TOLL-LIKE RECEPTORS:
STRUCTURE, LOCALIZATION
AND FUNCTION
TLRs are type I transmembrane glycoproteins consist-
ing of three domains: leucine rich ligand binding ectodo-
main, transmembrane region, and cytoplasmic TIR-do-
main (the Toll/interleukin-1 receptor domain). Ecto-
domain contains multiple leucine rich repeats (LRRs)
which are crucial in recognition and binding of pathogen
motifs and also in forming characteristic horseshoe shape
of TLRs, a structure important in ligand binding and
downstream signaling (6). TIR-domain dimerizes after
the ligand binding in the ectodomain enabling the re-
cruitment of TIR domain containing adaptor molecules
which transduce the signal downstream: MyD88 (mye-
loid differentiation factor 88), MAL (MyD88 adaptor-
-like), TRIF (Toll receptor-associated activator of inter-
feron) and TRAM (Toll receptor-associated molecule) (2,
6). All TLRs except TLR3 use MyD88 for signal trans-
duction, and TLR3 depends on TRIF. TLR4 can activate
both MyD88 and TRIF. TLRs can form homodimers (like
TLR3-TLR3) or heterodimers (such as TLR1-TLR2 and
TLR2-TLR6) (2). Due to differences in ectodomain,
different TLRs bind different PAMPS, such as lipids and
lipoproteins (TLR1, TLR2, TLR4 and TLR6), proteins
(TLR5 and mouse TLR11), and microbial nucleic acids
(TLR3, TLR7, TLR8 and TLR9), while ligands of TLR10
and mouse TLR12 and TLR13 have not yet been identi-
fied (7). Nature of ligands they bind determines the
location of TLRs in the cell: TLR1, TLR2, TLR4, TLR5
and TLR6 bind components of pathogen envelope or cell
wall and are expressed on the surface of the cell (as well
as TLR10), while TLR3, TLR7, TLR8 and TLR9 bind
nucleic acids and are mainly located in the endoplasmic
reticulum membrane or endosomal membrane (2). TLRs
are mainly expressed in lymphoid tissues, innate immune
cells (dendritic cells, macrophages, monocytes, polymor-
phonuclear leukocytes, NK cells) and lymphocytes T
and B. However, they can also be expressed in different
cell types, including cancer cells and cancer cell lines (5,
8). In normal tissues, TLRs are highly expressed in many
epithelial cells (9).
3. TOLL-LIKE RECEPTORS IN CANCER
TLRs participate in many important cellular proces-
ses: cell proliferation, survival, apoptosis, cell migration,
metastasis and angiogenesis. Due to their important role
in inflammation, it is considered that they can have a
pro-tumorigenic and anti-tumorigenic function, an effect
known as a „double edged sword“ (10, 11). In some cases
enhanced TLR activation can lead to apoptosis of cancer
cells and more efficient elimination of tumor cells by
immune system, while in others it may support tumori-
genesis by promoting chronic inflammation (8, 12, 13).
TLR signaling has been implicated in various autoim-
mune and inflammatory diseases and chronic inflamma-
tion is known to create a microenvironment rich in growth
and survival factors and has been linked with develop-
ment of many types of cancer (13). TLR expression was
reported in several cancer types and cancer cell lines. It
was found that TLR4 and TLR5 are expressed in gastric
epithelium infected with Helicobacter pylori as well as in
precursor lesions and in gastric cancer cells (14). It is
considered that TLRs enable cells to interact with H.
pylori which can induce tumorigenic factors and may
promote cancer development. TLR expression has also
been found in colon cancer, hepatocellular carcinoma,
ovarian and cervical cancers, breast and prostate cancers,
lung cancer, melanoma and neuroblastoma (9). TLR
expression in cancer cells has been linked with tumor
progression, evasion of immune system surveillance,
apoptosis and survival. TLR4 expression in lung cancer
cells is linked with production of immunosuppressive
cytokines (TGFb), angiogenic factors VEGF and IL-8,
and with increased resistance to apoptosis (15). Silencing
of TLR4 expression in breast cancer cell line MDA-
-MB-231 significantly decreased cell proliferation and
production of proinflammatory cytokines IL-6 and IL-8
(16). In ovarian cancer cells and cell lines TLR4 activa-
tion by lipopolysaccharide or Paclitaxel activated NF-kB,
promoted production of IL-8, IL-6, VEGF and MCP-1,
and inhibited Paclitaxel mediated apoptosis, while TLR4
silencing lead to loss of resistance to Paclitaxel (17).
TLR2 mRNA expression was significantly higher in spo-
radic colorectal cancer cells than in noncancerous cells
which could implicate its role in cancerogenesis (18).
4. THE POLYMORPHISMS OF TLR GENES
Single nucleotide polymorphisms (SNPs) may often
cause no change in protein function and pass unnoticed,
but can also lead to amino acid substitutions and changes
in protein function and stability, splicing, mRNA stabi-
lity, post-translational modifications or regulation of ex-
pression (Figure 1A and 1B) (19). SNPs in TLR ecto-
domain (in LRRs) can affect binding of ligands and
SNPs in transmembrane domain may alter receptor lo-
calization and trafficking in the cell. SNPs in the cyto-
plasmic domain may lead to defects in recruitment of
adapter proteins, receptor dimerization and internaliza-
tion after ligand binding (20, 21). TLR polymorphisms
have been linked with susceptibility or protective effect in
various diseases, mainly infective and inflammatory, but
also in cancer (Table 1) (20).
4.1. TLR1, TLR6 and TLR10
polymorphisms
Receptors TLR1, TLR6 and TLR10 have similar struc-
tures and genes TLR1, TLR6 and TLR10 form a single
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gene cluster on the chromosome 4p14 (22). Receptor
TLR1 recognizes triacylated lipoprotein, TLR6 binds
diacylated lipoprotein and so far no specific ligand has
been linked with TLR10 (7). To bind ligands TLR1 and
TLR6 must form dimers with TLR2, while TLR10 ho-
modimerizes or heterodimerizes with TLR1 or TLR2.
There have been several association studies between SNPs
in TLR10-TLR1-TLR6 gene cluster and prostate cancer
risk, but with highly contradictory results regarding even
the same investigated polymorphisms (23, 24, 25). Finally,
pooled analysis on genotype data from three case control
studies with more than 3,000 prostate cancer patients and
more than 2,500 controls of European ancestry found no
overall association between polymorphisms in TLR10-
-TLR1-TLR6 gene cluster or TLR4 gene with prostate
cancer risk (26). However, polymorphisms in TLR10-
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Figure 1. Position of cancer risk associated TLR polymorphisms within genes (A) and proteins (B). A) Polymorphisms (four-angled star) in TLR
genes. B) Location of polymorphisms (black triangle) in TLR proteins: ectodomain leucine rich repeats (light grey), transmembrane region (black
wavy line) or Toll/interleukin-1 receptor (TIR) domain (dark grey box). After ligand binding all TLRs interact with myeloid differentiation factor
88 (MyD88) except TLR3 who interacts with Toll receptor-associated activator of interferon (TRIF). TLR4 can interact with MyD88 and TRIF.
Downstream signaling leads to the activation of transcription factors: activator protein 1 (AP1), nuclear factor kB (NF-kB) and interferon-
-regulatory factors (IRFs).
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-TLR1-TLR6 gene cluster have been associated with
lymphoma, meningioma and breast cancer risk. TLR6
polymorphism rs5743815 (c.1280T>C, Val427Ala) was
found to be associated with significantly increased non-
-Hodgkin’s lymphoma risk (27). A polymorphism close
to TLR10 gene, rs10008492 (C>T), was associated with
significantly increased risk of non-Hodgkin’s lymphoma,
while polymorphism close to TLR1 gene, rs4833103 (C>A),
was associated with decreased risk of this tumor type deve-
lopment (28). Both SNPs are in linkage disequilibrium
with a TLR1 polymorphism rs5743618 (c.1805G>T,
Ser602Ile) which is known to affect ligand binding (28).
TLR10 polymorphism rs11466657 (Ex3-1099T>C, re-
verse strand, Ile473Thr) was associated with decreased
meningioma risk (29) and polymorphism between genes
TLR1 and TLR6, rs7696175 (C>T), with increased breast
cancer risk in African American population (30).
4.2. TLR2 gene polymorphisms
4.2.1. TLR2 -196 to -174 del polymorphism
TLR2 gene maps to 4q32 and TLR2 receptor binds
lipoproteins, peptidoglycans and glycoproteins (22).
Special attention has been focused on TLR2 -196 to -174
del (D22) functional polymorphism in 5’ untranslated
region known to reduce TLR2 transcriptional activity.
There have been several studies regarding impact of D22
polymorphism on gastric cancer development, but with
contradictory results, especially in Japanese and Chinese
populations (31, 32, 33). Recently, D22 polymorphism
was associated with increased gastric cancer risk in Bra-
zilian population (34) and with higher hepatitis C viral
load and was more frequent in hepatitis C associated
hepatocellular carcinoma patients than controls in Ger-
many (35). Also, D22 polymorphism was found to be
more frequent in breast cancer patients than in healthy
controls in Greece (36). It was also associated with in-
creased prostate (37), gallbladder (38) and cervical can-
cer risk (39) in India.
4.2.2. Other TLR2 polymorphisms
Microsatellite GT number repeat polymorphism is
located in intron 2 of TLR2 gene. Middle (M) size 'allele'
with 20 and 21 GT repeats is found to be associated with
decreased colorectal cancer risk in Croatian population
when compared with shorter (S) and larger (L) number
of repeats (40), suggesting possible impact of polymor-
phism on receptor transcriptional activity. Also, TLR2
polymorphism rs3804100 (c.1350T>C, Ser450Ser) was
associated with increased mucosa associated lymphoid
tissue (MALT) lymphoma risk (28), and together with
rs3804099 (c.597T>C, Asn199Asn) with decreased he-
patocellular carcinoma risk (41), but not with breast
cancer risk (42).
4.3. TLR3 gene polymorphisms
TLR3 maps to 4q35 and binds double stranded RNA
(22). There have been few reports of TLR3 polymor-
phisms in cancer and mainly with no cancer risk asso-
ciation. Those which were proven to be associated in-
clude: (1) TLR3 polymorphism 829A>C, associated with
increased nasopharyngeal carcinoma risk in Chinese po-
pulation (43), and (2) TLR3 polymorphism rs3775291
(c.1234 C>T, Leu412Phe) which was implicated as a
negative prognostic factor for survival of stage II colo-
rectal cancer patients (44).
4.4. TLR4 gene polymorphisms
TLR4 gene maps to 9q32-33 and TLR4 receptor binds
lipopolysaccharide (22). TLR4 polymorphisms have been
investigated in numerous studies and in various cancer
types, with main focus on polymorphisms rs4986790
(c.896A>G, Asp299Gly) and rs4986791 (c.1196 C>T,
Thr399Ile). Both polymorphisms lead to amino acid sub-
stitution in extracellular domain of the TLR4 receptor
and are known to diminish response to lipopolysaccha-
ride. Polymorphism Asp299Gly was found to be more
frequent in colorectal cancer patients than healthy con-
trols (40). It was also later associated with increased non-
-cardia gastric cancer risk, but not with gastric cardia
carcinoma or esophageal cancer (45). Recently, associa-
tion with increased gastric cancer risk was confirmed in
Brazilian population (34) and meta analysis based on
data from 22 studies confirmed association with increased
gastrointestinal cancer risk, but with decreased prostate
cancer risk (46). Also, Asp299Gly was more frequent in
breast cancer patients than healthy controls in Greece
(36). On the contrary, no such association was found in
breast cancer patients from Croatian population (42).
Therefore it is still under the question whether this poly-
morphism could be used as a marker for breast cancer
susceptibility. Polymorphism Asp299Gly was also asso-
ciated with increased MALT lymphoma and Hodgkin’s
lymphoma risk (47), but not with non-Hodgkin’s lym-
phoma risk (28). Interestingly, Asp299Gly was associated
with improved survival in melanoma patients (48). Poly-
morphism Thr399Ile was found to be associated with
increased gastrointestinal cancer risk and increased over-
all cancer risk in recent meta analysis (46), but there have
also been reports of no association with gastric cancer (34),
possibly due to small sample size. Also, polymorphism
Thr399Ile was associated with increased nasopharyngeal
carcinoma risk in China (49) and increased gallbladder
cancer risk in India (38).
4.4.1. Other TLR4 polymorphisms
There have been reports regarding several TLR4 poly-
morphisms and cancer risk in China. TLR4 polymor-
phism 11350G>C was associated with increased naso-
pharyngeal carcinoma risk (50). rs1927911 (T>C) and
rs10759931 (G>A) were associated with increased pro-
state cancer risk (51) and rs10759932 (T>C) with reduc-
ed gastric cancer risk (52).
4.5. TLR5 gene polymorphisms
TLR5 gene maps to 1q33.3 and TLR5 receptor binds
flagellin (22). TLR5 polymorphisms have mainly not
been associated with cancer risk. However, TLR5 poly-
morphism rs5744174 (c.1846T>C, Phe616Leu), which
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affects ligand binding, was recently associated with in-
creased gastric cancer risk in China, with especially high
risk in patients infected with H. pylori (33).
4.6. TLR7 and TLR8 gene
polymorphisms
TLR7 and TLR8 share a common locus on chromo-
some Xp22 and their receptors bind single stranded RNA
(22). So far polymorphisms in TLR7 and TLR8 have not
been firmly associated with cancer risk.
4.7. TLR9 gene polymorphisms
TLR9 gene maps to 3p21.3, and TLR9 receptor binds
CpG rich bacterial DNA (22). Recently, it was reported
that TLR9 polymorphism Arg892Trp causes hypores-
ponsiveness to CpG oligodeoxynucleotides (53). TLR9
polymorphism rs5743836 (-1237T>C) was associated
with significantly increased Hodgkin’s lymphoma risk, as
well as A allele of rs352140 (2848A>G, Pro545Pro) (54).
Recently, TLR9 rs187084 (-1486T>C) and rs352140
(2848C>T, Pro545Pro) polymorphisms were found to
be associated with increased cervical cancer risk in Po-
land (55).
5. CONCLUSION
Toll-like receptors have numerous important roles in
innate and acquired immunity. Wide spectrum of their
signaling pathways and downstream effectors makes them
crucial in development of infective diseases, chronic in-
flammation and cancer. Polymorphisms in TLR genes
can reduce receptor function, cause over excessive sig-
naling or change the level of transcription, and therefore
influence disease development and progression. Although
there have been numerous studies regarding impact of
polymorphisms on TLR function and disease develop-
ment, there is a lot of controversial and yet uncertain
data. Contradictory results in different studies may reflect
insufficient sample size, ethnicity or age differences, in-
fection with undetected pathogens or other environmental
factors. The role of TLR10-TLR1-TLR6 polymorphisms in
prostate cancer is controversial and so far those poly-
morphisms cannot be firmly associated with prostate
cancer risk.
Epstein-Bar virus (EBV) infection plays important
role in development of non-Hodgkin’s lymphoma as
well as nasopharyngeal carcinoma. The association of
polymorphisms in TLR genes with increased cancer risk
has been shown in lymphoma (TLR6 rs5743815) and
nasopharyngeal carcinoma (TLR3 829A>C and TLR4
rs4986791). This may affect virus recognition and im-
mune response to pathogens leading to increased disease
susceptibility.
Discrepancies regarding TLR2 -196 to -174 del poly-
morphism and gastric cancer risk are similar to those in
TLR4 (rs4986790 and rs4986791). Both receptors are
important in H. pylori infection, which has been im-
plicated in gastric cancer development, and it is possible
that they influence cancer development only in presence
of H. pylori infection. Conflicting outcome may also
result from different types of cancer investigated, only
noncardia gastric cancer or all gastric cancer types. Des-
pite somewhat contradictory results, TLR2 -196 to -174
del polymorphism and TLR4 rs4986790 and rs4986791
have been linked with various cancer types (gastric, he-
patocellular, breast and prostate cancer) in various popu-
lations (Japanese, European, Indian) and their role in
carcinogenesis and modulation of immune response to
pathogens should be further investigated.
Little and less is known about effects of polymor-
phisms in TLR3, TLR5, TLR7 and TLR8 genes on cancer
risk and development. TLR3 polymorphism 829A>C
has been implicated in nasopharyngeal carcinoma risk
and TLR5 polymorphism rs5744174 in gastric cancer
risk, but possible impact of TLR7 and TLR8 polymor-
phisms on cancer risk still remains a mystery.
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